ABRA C-terminal-like protein (ABRACL)

ABRA C-terminal-like protein (ABRACL) is a small, low-molecular-weight (approx. 9 kDa, 81 amino acids) non-typical winged-helix protein, sharing structural similarity with the C-terminal actin-binding domain of ABRA (Actin-Binding Rho-Activating protein)[1][2][5]. Unlike classical DNA-binding winged-helix proteins, ABRACL likely does not function as a transcription factor, but rather modulates actin cytoskeleton dynamics. Its physiological role is not fully elucidated, but evidence supports involvement in actin filament regulation, cell migration, and cell proliferation, notably in cancer cells where ABRACL is often upregulated[1][3][5]. It is also expressed in developing neurons and implicated in neuronal migration, axon growth, and synapse formation, with a conserved role in mammalian brain development[1]. Elevated expression in certain cancers (including gastric, esophageal, breast, bladder, and endometrial cancers) is associated with poor prognosis, suggesting utility as a cancer biomarker and potential therapeutic target[3]. No direct interacting drugs, mechanisms, or notable safety concerns have been reported for ABRACL-targeted intervention as of the latest data.

Other names

Costars family protein ABRACLC6orf115HSPC280PRO2013CostarsABRA C-terminal-like protein